Brian R. Murphy
81Patents
15h-index
49Co-inventors
84Inventor score
Filing activity: Jun 18, 1975 → Jul 19, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5922326A | Attenuated respiratory syncytial virus vaccine compositions | Chemistry; Metallurgy | 55 | Expired |
| US5762905A | Human neutralizing monoclonal antibodies to respiratory syncytial virus | Chemistry; Metallurgy | 55 | Expired |
| US3992522A | Temperature-sensitive recombinant mutant viruses and a process for producing same | Emerging Cross-Sectional Technologies | 48 | Expired |
| US4552758A | Human use of avian-human reassortants as vaccines for influenza A virus | Chemistry; Metallurgy | 46 | Expired |
| US6685942B1 | Human neutralizing monoclonal antibodies to respiratory syncytial virus | Emerging Cross-Sectional Technologies | 45 | Expired |
| US5993824A | Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences | Chemistry; Metallurgy | 38 | Expired |
| US7846455B2 | Attenuated chimeric respiratory syncytial virus | Chemistry; Metallurgy | 29 | Expired |
| US6713066B1 | Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2 | Chemistry; Metallurgy | 25 | Expired |
| US4683137A | Temperature sensitive reassortant viruses and a vaccine against equine influenza | Emerging Cross-Sectional Technologies | 25 | Expired |
| US6689367B1 | Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences | Chemistry; Metallurgy | 24 | Expired |
| US7488477B2 | Neutralizing monoclonal antibodies to respiratory syncytial virus | Chemistry; Metallurgy | 23 | Expired |
| US7208161B1 | Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences | Chemistry; Metallurgy | 22 | Expired |
| US7704509B2 | Recovery of recombinant human parainfluenza virus type 1 (HPIV1) from cDNA and use of recombinant HPIV1 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens | Chemistry; Metallurgy | 18 | Expired |
| US7709007B2 | Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences | Chemistry; Metallurgy | 15 | Active |
| US8221759B2 | Neutralizing monoclonal antibodies to respiratory syncytial virus | Chemistry; Metallurgy | 15 | Active |
| US7192593B2 | Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens | Chemistry; Metallurgy | 14 | Expired |
| US7517531B2 | Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4 | Emerging Cross-Sectional Technologies | 13 | Active |
| US7364737B2 | Human neutralizing monoclonal antibodies to respiratory syncytial virus | Emerging Cross-Sectional Technologies | 13 | Expired |
| US6410023B1 | Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene | Chemistry; Metallurgy | 13 | Expired |
| US7250171B1 | Construction and use of recombinant parainfluenza viruses expressing a chimeric glycoprotein | Chemistry; Metallurgy | 13 | Expired |
| US8075903B2 | Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1, 2, 3, and 4 or antigenic chimeric dengue viruses 1, 2, 3, and 4 | Emerging Cross-Sectional Technologies | 12 | Active |
| US7226602B2 | Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses | Emerging Cross-Sectional Technologies | 11 | Expired |
| US6923971B2 | Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes | Chemistry; Metallurgy | 9 | Expired |
| US7704491B2 | Recombinant human metapneumovirus and its use | Chemistry; Metallurgy | 9 | Expired |
| US8632782B2 | Recombinant attenuated dengue viruses comprising mutations in NS5 and the 3′ untranslated region | Emerging Cross-Sectional Technologies | 9 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.